| Chronic Lymphocytic Leukemia |
1 |
1 |
| Biologic Therapy |
0 |
0.9 |
| CAR-T |
0 |
0.99 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.28 |
| Lymphoma |
0 |
0.22 |
| Refractory |
0 |
0.22 |
| B-Cell Lymphoma |
0 |
0.2 |
| Leukemia |
0 |
0.18 |
| Canada |
0 |
0.11 |
| Remission |
0 |
0.11 |
| Residual Disease |
0 |
0.11 |
| Patient Safety |
0 |
0.09 |
| Toxicology |
0 |
0.09 |
| Bone Marrow |
0 |
0.08 |
| T-Lymphocyte |
0 |
0.08 |
| Antigens |
0 |
0.06 |
| Blood |
0 |
0.06 |
| Bone |
0 |
0.06 |
| Cancer |
0 |
0.06 |
| Corticosteroids |
0 |
0.06 |
| Cytokines |
0 |
0.06 |
| Drug and Treatment Safety |
0 |
0.06 |
| Hematology |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Lymphocytes |
0 |
0.06 |
| Lymphohistiocytosis |
0 |
0.06 |
| Neurotoxicity |
0 |
0.06 |
| Pennsylvania |
0 |
0.06 |
| Receptors |
0 |
0.06 |